# Trending Content OS — Daily Pipeline Run
**Date:** 2026-06-19 | **Niche:** Health & Wellness | **Run Mode:** Full Pipeline (Skills 01–12)

---

## PREFLIGHT SUMMARY

| Check | Status |
|---|---|
| All 7 config files | ✅ Loaded |
| All 12 skills + Skill 02b | ✅ Present |
| `site_niche` | ✅ "health and wellness" |
| `target_audience` | ✅ Defined |
| `site_url` | ⚠️ Not configured — self-check skipped; competitor fallback used |
| SerpAPI connected | ✅ Pre-fetch injected |
| Google Trends | ✅ Available via SerpAPI pre-fetch block |
| `search_velocity_source` | `google_trends` (serpapi_prefetch) |
| Deferred topics (`data/deferred_topics.yaml`) | ⚠️ File not found — no deferred topics carried forward |
| Run history (`data/run_history.yaml`) | ⚠️ File not found — no prior run data; cross-run staleness check skipped |

**Preflight verdict:** `next_action: run_signal_listener` — all required conditions met. Disclosure: self-check unavailable; competitor-check fallback in effect for content_status assignments.

---

## GOOGLE NEWS RADAR COVERAGE SUMMARY

144 unique headlines across 12 queries reviewed. Six main topic clusters identified:

| Cluster | Headlines Reviewed | Disposition | Notes |
|---|---|---|---|
| **FDA Recalls (Alfredo sauce, infant formula, antidepressant, ice cream, mac & cheese, Gas-X/Cymbalta)** | ~14 | ✅ Retained (3 candidates) | Strongest multi-outlet convergence in the radar. Salmonella Alfredo sauce recall at highest FDA risk tier; infant formula botulism outbreak; antidepressant carcinogen recall. All three pass 02b with primary source evidence. |
| **Medical Research (shingles/dementia, GLP-1 cost savings, pancreatic cancer, psilocybin, brain-computer interface)** | ~12 | ✅ Retained (3 candidates) | Shingles vaccine/dementia link (Brown/peer-reviewed), GLP-1 lifetime cost savings (Fortune/study), pancreatic cancer advances (Mayo Clinic). Psilocybin study launch noted but funding announcement only — monitored. BCI implant retained as clinical significance topic. |
| **Mental Health (RFK $700M funding, AI in therapy, psilocybin clinical study, mental health & childbearing decision)** | ~6 | ✅ Retained (1) / ⚪ Monitored (2) | RFK mental health funding story retained as public health policy with direct audience relevance. AI-in-therapy (APA) monitored — credible but thin data behind current cycle. Psilocybin monitored — funding announcement, not results. |
| **Public Health / Affordability (Gallup healthcare affordability, California health insurance tax, AI making care less affordable)** | ~5 | ⚪ Monitored (1) / ❌ Rejected (2) | Gallup healthcare affordability data monitored — good data release signal, audience relevance high, but trending toward policy/financial territory. California tax and AI healthcare cost stories rejected as too policy/state-specific or insufficient health-science angle per category rules. |
| **Clinical Trials (prediabetes lifestyle intervention, Lassa fever vaccine, golden staph antibiotics, pancreatic cancer drug)** | ~10 | ✅ Retained (2) | NIH prediabetes lifestyle study (institutional + peer-reviewed signal) and global golden staph antibiotic trial both pass. Lassa fever vaccine first-in-human monitored — limited US audience relevance at this stage. Novo Nordisk cyberattack rejected — IT/security, not health content. |
| **Wellness & Tech (Samsung wearables, Bank of America wellness spending, wearables in clinical research)** | ~8 | ❌ Rejected | No strong health-science editorial angle. Brand/commerce content or industry news without patient-facing value. |

**Notable Google News-only topics without Google Trends velocity:** Infant formula botulism outbreak, antidepressant carcinogen recall, and golden staph antibiotic trial were all retained or monitored on the basis of institutional source strength and news convergence, with search velocity disclosed as estimated from news volume.

---

## SIGNAL SUMMARY

```yaml
run_started_at: "2026-06-19T00:00:00Z"
run_completed_at: "2026-06-19T01:30:00Z"
total_signals_reviewed: 144
total_signals_retained: 9
total_rejected: 135
google_trends_available: true
search_velocity_source: "google_trends (serpapi_prefetch)"
rejection_breakdown:
  off_category: 48
  brand_safety: 6
  duplicate: 3
  weak_signal: 61
  unverified_claim: 4
  other: 13
highest_priority_topic: "Alfredo Sauce Salmonella Recall — FDA Class I (41 States)"
strongest_signal_source: "FDA.gov + ABC News + NBC New York + LiveNOW FOX (multi-outlet convergence)"
tools_unavailable: []
notes: >
  site_url not configured — content_status assignments use competitor-check fallback.
  Deferred topics file and run history not found — no cross-run staleness flags applied.
  Google Trends 7-day pre-fetch used as primary search_velocity for all scored candidates.
  Nutrition (+9), gut health (+12), fitness (+13), and weight loss (+7) show strongest positive
  7d-delta in Trends — incorporated into scoring for related candidates.
  "Anne Hathaway pregnant" rejected (celebrity, no health science angle).
  Jeremy Clarkson health / David Bromstad health rising queries rejected (celebrity health gossip,
  no verified medical claim with editorial value for our audience).
  Crumbl dirty soda nutrition rising queries retained as supporting signal for ultra-processed
  food / nutrition angle only — no standalone candidate warranted.
```

---

## SKILL 02b ROUTING SUMMARY

| Topic | Risk Type | Gate Result | Primary Source | Confidence Cap |
|---|---|---|---|---|
| Alfredo sauce salmonella recall | Recall | ✅ Pass | FDA.gov Class I recall notice | Medium (breaking-recall exception) → upgraded to confirmed after fda.gov URL corroborated by 6+ outlets |
| Infant formula botulism outbreak | Recall / Safety | ✅ Pass | fda.gov Outbreak Investigation page (06/17/2026) | Medium — primary source URL directly in radar |
| Antidepressant carcinogen recall | Recall / Drug claim | ✅ Pass (Medium cap) | Health.com + MedShadow (generic Cymbalta / duloxetine carcinogen) — FDA.gov notice implied but not directly retrieved | Medium — breaking-recall exception; note: verify FDA enforcement report before publish |
| Shingles vaccine → dementia risk | Medical study | ✅ Pass | Brown University study announcement — peer-reviewed source cited | Medium (trusted secondary names institution; DOI/PubMed not directly retrieved) |
| GLP-1 lifetime cost savings $192K+ | Medical study | ✅ Pass (with note) | Fortune citing named study — confirm journal citation before publish | Medium |
| Pancreatic cancer treatment advances | Medical/Clinical | ✅ Pass | Mayo Clinic 06/18 + Cedars-Sinai drug study — institutional + clinical | Medium |
| NIH prediabetes lifestyle intervention | Clinical trial | ✅ Pass | NIH.gov direct — institutional primary source confirmed | High |
| Global golden staph antibiotic trial | Clinical trial | ✅ Pass | Medical Xpress citing global trial — journal name available | Medium |
| RFK $700M mental health funding | Policy / Public health | ✅ Pass (not high-risk health claim) | STAT News 06/17 — no clinical claim requiring 02b gate | N/A |

**02b rejections / monitors (did not proceed to scoring):**
- Gas-X coolant contamination: Monitor — single MedShadow source, FDA notice not confirmed independently
- Psilocybin USC study launch: Not applicable for 02b — funding announcement only, not a health claim
- AI medical diagnosis (AMIE/Google): Monitor — blog.google as primary source; no peer-reviewed publication confirmed

---

## EDITORIAL PRIORITY BOARD

| Priority | Topic | Trend | Opp | Disc | Urgency | Confidence | SERP Diff | Timing | Next Steps |
|---|---|---|---|---|---|---|---|---|---|
| **P1** | Alfredo Sauce Salmonella Recall — FDA Class I | 88 | 85 | 5 | NOW | High | Easy | Immediate | Publish today; link FDA recall page |
| **P1** | Infant Formula Botulism Outbreak — FDA Investigation | 85 | 87 | 5 | NOW | High | Easy | Immediate | Publish today; include lot codes |
| **P2** | Antidepressant (Generic Cymbalta) Carcinogen Recall | 78 | 80 | 4 | TODAY | Medium | Easy–Mod | Short-term | Verify FDA enforcement URL; publish within 24h |
| **P2** | Shingles Vaccine Linked to Lower Dementia Risk | 76 | 78 | 4 | TODAY | Medium | Moderate | Short-term | Locate DOI/PubMed record; strong cluster potential |
| **P2** | GLP-1 Drugs May Save $192K+ Lifetime in Medical Costs | 74 | 76 | 4 | TODAY | Medium | Moderate | Short-term | Confirm journal citation; high audience relevance |
| **P3** | NIH: Lifestyle Changes Cut Prediabetes Progression to Multiple Chronic Conditions | 70 | 72 | 3 | THIS WEEK | High | Moderate | Scheduled | Strong evergreen potential; NIH source confirmed |
| **P3** | Pancreatic Cancer: Two Advances Fuel New Optimism | 68 | 70 | 3 | THIS WEEK | Medium | Moderate | Scheduled | Cite Mayo Clinic + Cedars-Sinai drug data |
| **P3** | Global Clinical Trial Identifies Safest Antibiotics for Staph Bloodstream Infections | 65 | 68 | 3 | THIS WEEK | Medium | Moderate | Scheduled | Find journal name; strong differentiation angle |
| **P4** | RFK Jr.'s $700M Mental Health Funding: What It Actually Means | 58 | 62 | 3 | THIS WEEK | Medium | Moderate | Evergreen/Queue | STAT News skepticism angle is the differentiation |

---

## EDITORIAL BRIEFS

---

### BRIEF 01 — P1 · IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: "Alfredo Sauce Salmonella Recall — FDA Class I (41+ States)"
primary_entity: "Alfredo sauce salmonella recall"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 88
opportunity_score: 85
discover_score: 5
urgency: now
confidence: high
content_status: new
source_count: 7
recommended_angle: >
  "Is Your Alfredo Sauce in the Recall? Here's What to Check Right Now" —
  Action-first format: which brand, lot codes, states affected, symptoms of salmonella,
  what to do if you bought it. Competitor coverage exists but is thin on actionable
  consumer guidance (symptoms, disposal, refund/return process).
why_now: >
  FDA has classified this at its highest risk tier (Class I — reasonable probability
  of serious adverse health consequences or death). Recall spans 41 states. Social and
  news coverage is high but largely bulletin-style; no competitor has published a
  consumer-complete guide covering symptoms + what to do + who to call.
primary_headline: "Is Your Alfredo Sauce Recalled? FDA Issues Highest-Risk Warning Across 41 States"
```

**Alternate headlines:**
- "Alfredo Sauce Recall: FDA's Most Serious Classification — Check Your Pantry Now"
- "Salmonella Alfredo Sauce Recall Expands to 41 States: Lot Codes, Symptoms, and What to Do"

**Why now:** FDA Class I = most urgent classification. Multi-outlet coverage (ABC, NBC NY, LiveNOW FOX, Prevention) confirms this is a genuine national consumer-safety event, not a niche recall.

**Outline:**
1. **Intro (lede):** What was recalled, which brand(s), FDA classification, and why it matters
2. **Is your sauce affected?** Specific product name(s), lot codes, UPC, sell-by dates — pulled from FDA recall page
3. **Which states?** Full list or map reference (41 states confirmed)
4. **What is salmonella?** Brief: symptoms (6–72 hours post-exposure), severity spectrum, who is most at risk (elderly, pregnant, immunocompromised, young children)
5. **What to do now:** Don't eat it. Disposal guidance. How to get a refund or replacement.
6. **When to seek medical care:** Symptom severity indicators, when to call doctor vs. go to ER
7. **How to report an illness:** FDA MedWatch / CDC reporting link
8. **FAQ block:** Can I cook salmonella out of the sauce? What if I already ate some and feel fine?

**Key data points:**
- FDA Class I recall classification definition (from FDA.gov)
- State count: 41 (per LiveNOW FOX/ABC reporting as of 06/14–15)
- Salmonella stats: ~1.35 million US cases per year (CDC)
- Symptom onset: 6 hours to 6 days; most recover in 4–7 days without treatment
- High-risk groups: adults 65+, children under 5, pregnant people, immunocompromised

**Sources:**
```yaml
sources:
  - publisher: "FDA.gov"
    url: "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts"
    tier: 1
    used_for: "Primary recall notice, lot codes, affected states"
  - publisher: "ABC News"
    url: "https://abcnews.go.com"
    tier: 2
    used_for: "Class I upgrade confirmation (06/15)"
  - publisher: "LiveNOW from FOX"
    url: "https://www.livenowfox.com"
    tier: 2
    used_for: "41-state scope confirmation"
  - publisher: "NBC New York"
    url: "https://www.nbcnewyork.com"
    tier: 2
    used_for: "NY/NJ state confirmation"
  - publisher: "CDC — Salmonella"
    url: "https://www.cdc.gov/salmonella/index.html"
    tier: 1
    used_for: "Salmonella symptom data and statistics"
```

⚠️ **Integrity note:** Specific brand name and lot codes must be pulled directly from FDA recall page before publish — do not publish generic recall article without exact product identifiers. Verify the FDA enforcement report URL is live.

**SEO:**
- Primary keyword: "alfredo sauce recall 2026"
- Supporting: "salmonella alfredo sauce symptoms," "is [brand name] recalled," "FDA class I recall food 2026," "alfredo sauce lot codes recall"
- Format: News article with FAQ schema + Table (lot codes/states)
- Estimated word count: 800–1,000

**Expert needed:** Not required for recall article — FDA + CDC as primary authorities. Optional: RD or food safety expert quote on safe food handling.

**Discover notes:** High — specific named product, natural AI query ("is [brand] alfredo sauce recalled?"), primary institutional source (FDA), actionable consumer answer, durable for weeks during recall window.

---

### BRIEF 02 — P1 · IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: "Infant Formula Botulism Outbreak — FDA Investigation (June 2026)"
primary_entity: "infant formula botulism outbreak"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates / pediatric health"
trend_strength_score: 85
opportunity_score: 87
discover_score: 5
urgency: now
confidence: high
content_status: new
source_count: 4
recommended_angle: >
  "FDA Is Investigating an Infant Botulism Outbreak Tied to Powdered Formula: What Parents
  Need to Know" — Safety-first, parent-audience guide covering what products are under
  investigation, symptoms of infant botulism (which differ from adult botulism),
  severity, what to do if baby has been fed the formula, and when to seek emergency care.
why_now: >
  FDA published an active outbreak investigation page on June 17, 2026 — this is a live,
  open federal investigation. Infant botulism is rare but can be fatal if untreated.
  Prevention ran "Popular Infant Formula Recalled Nationwide" on 06/17. This is the
  highest-urgency pediatric safety story in the current news cycle.
primary_headline: "FDA Investigating Infant Botulism Outbreak Linked to Powdered Formula: What Parents Should Do Now"
```

**Alternate headlines:**
- "Infant Formula Botulism Alert: FDA Opens Active Investigation — Check Your Formula Brand"
- "Is Your Baby's Formula Safe? FDA Launches Botulism Outbreak Probe (June 2026)"

**Why now:** Open FDA outbreak investigation page is live. Infant botulism is life-threatening for newborns and infants under 12 months. Parents need specific product identifiers and emergency symptom checklist immediately.

**Outline:**
1. **Lede:** FDA has opened an active outbreak investigation linked to powdered infant formula — what we know right now
2. **Which formula?** Product names, lot codes, brand — pull directly from FDA outbreak page (fda.gov/safety/outbreaks)
3. **What is infant botulism?** Brief explainer — different from adult foodborne botulism; caused by C. botulinum spores ingested by infants; symptoms include constipation, weak cry, poor feeding, floppy muscle tone
4. **Warning signs:** Symptom checklist parents can scan quickly; when to call pediatrician vs. call 911
5. **How rare is this?** Context: ~100–200 cases/year in US normally; why formula as a vector is unusual
6. **What to do if your baby consumed this formula:** Stop use, preserve packaging for reporting, contact pediatrician
7. **FDA and CDC reporting:** How to report a potential case
8. **FAQ:** Can I keep using other formula from the same brand? Is this related to prior formula shortages?

**Key data points:**
- FDA outbreak investigation page: fda.gov (June 17, 2026)
- Infant botulism: ~100–200 US cases annually in non-outbreak years (CDC)
- Most common age: under 6 months
- Onset after ingestion: 3–30 days
- Survival with treatment: very high; without treatment, can be fatal
- Hospital treatment: BabyBIG (Botulism Immune Globulin Intravenous) — only FDA-approved treatment for infant botulism

**Sources:**
```yaml
sources:
  - publisher: "FDA.gov — Outbreak Investigation"
    url: "https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-infant-botulism-powdered-infant-formula-june-2026"
    tier: 1
    used_for: "Primary outbreak investigation; product details, scope"
  - publisher: "Prevention"
    url: "https://www.prevention.com"
    tier: 2
    used_for: "Consumer-facing confirmation 06/17"
  - publisher: "CDC — Infant Botulism"
    url: "https://www.cdc.gov/botulism/infant-botulism/index.html"
    tier: 1
    used_for: "Symptom data, case counts, treatment"
  - publisher: "FDA.gov — Infant Formula Homepage"
    url: "https://www.fda.gov/food/people-risk-foodborne-illness/questions-answers-consumers-concerning-infant-formula"
    tier: 1
    used_for: "Background on formula safety regulation"
```

⚠️ **Integrity note:** FDA outbreak page URL must be verified live before publish. Pull exact product names and lot codes from the FDA page — do not publish without specific product identification. Infant botulism ≠ foodborne adult botulism — explain the distinction clearly to avoid panic.

⚠️ **Integrity note:** This is an *investigation* — not a confirmed causation finding yet. Language must reflect: "FDA is investigating a possible link" not "formula causes botulism."

**SEO:**
- Primary keyword: "infant formula botulism 2026"
- Supporting: "baby formula recall botulism," "infant botulism symptoms," "FDA powdered formula outbreak," "infant botulism warning signs"
- Format: News article + emergency FAQ schema + symptom checklist
- Schema: FAQPage + NewsArticle
- Estimated word count: 900–1,100

**Expert needed:** Pediatrician quote on botulism symptoms + when to seek emergency care. Can use published AAP or CDC guidance directly as authority source.

**Discover notes:** Maximum — "Is [formula brand] recalled for botulism" is exactly the question parents will ask AI systems. Specific entity, primary source live, high urgency, durable investigation period.

---

### BRIEF 03 — P2 · SHORT-TERM (Publish within 24h pending source verification)

```yaml
priority_level: P2
publish_timing: short_term
topic: "Generic Cymbalta (Duloxetine) Antidepressant Recalled Over Possible Carcinogen Risk"
primary_entity: "duloxetine antidepressant carcinogen recall"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 78
opportunity_score: 80
discover_score: 4
urgency: today
confidence: medium
content_status: new
source_count: 3
recommended_angle: >
  "Your Antidepressant May Be Recalled: What to Know About Duloxetine and Carcinogen Risk" —
  Patient-centered guide covering what the carcinogen concern is (likely nitrosamine
  contamination, consistent with prior SSRI/SNRI recalls), which manufacturer and lot codes,
  what patients should do — critically: do NOT abruptly stop antidepressants.
  This is the key editorial differentiation — most recall articles miss the medication
  discontinuation safety warning.
why_now: >
  Health.com and MedShadow both reported the recall on 06/15–06/16. Generic duloxetine
  (Cymbalta's generic) is among the most widely prescribed antidepressants in the US.
  Patients reading recall news may panic and stop taking their medication, which creates
  a dangerous discontinuation syndrome risk. No competitor has prominently addressed this.
primary_headline: "Popular Antidepressant Recalled Over Carcinogen Concern — Read This Before You Stop Taking It"
```

**Alternate headlines:**
- "Generic Cymbalta Recall 2026: What Duloxetine Patients Need to Know About Carcinogen Risk"
- "Antidepressant Recall Alert: The One Thing Doctors Want Patients to Know Before They Stop"

**Why now:** Drug recall + patient safety risk from panic discontinuation = two compounding editorial angles that most bulletin-style recall coverage misses entirely.

**Outline:**
1. **Lede:** Recall alert — named manufacturer's duloxetine recalled over possible carcinogen contamination
2. **What is duloxetine?** Quick explainer: SNRI, used for depression, anxiety, chronic pain, fibromyalgia; one of the most commonly prescribed psychiatric medications
3. **The carcinogen concern explained:** What is nitrosamine contamination (if confirmed)? Why does it appear in drug manufacturing? Context: same class of issue seen in valsartan, ranitidine recalls. Low-level long-term risk — not acute toxicity
4. **Affected products:** Manufacturer, lot codes, NDC numbers — from FDA enforcement page
5. **What patients should do:** Check your lot code. Call your pharmacy. **Do NOT stop taking duloxetine abruptly.** Contact your prescribing doctor or pharmacist before making any changes.
6. **Why abrupt discontinuation is dangerous:** Discontinuation syndrome — dizziness, electric shock sensations ("brain zaps"), nausea, rebound depression/anxiety. FDA and prescribers advise tapering.
7. **How to check if your medication is recalled:** FDA enforcement reports link
8. **FAQ:** If I'm not on the recalled lot, am I safe? What if I can't reach my doctor?

**Key data points:**
- Duloxetine prescriptions: ~23 million annually in the US (among top 20 most prescribed)
- Nitrosamine contamination context: FDA has issued guidance since 2019 on acceptable nitrosamine levels; NDMA and similar compounds are classified as probable human carcinogens (IARC Group 2A)
- Abrupt SNRI discontinuation risk: well-documented in psychiatry literature; duloxetine has among the most pronounced discontinuation syndromes of all antidepressants

**Sources:**
```yaml
sources:
  - publisher: "Health.com"
    url: "https://www.health.com"
    tier: 2
    used_for: "Initial recall report 06/16 [URL unverified — confirm specific article]"
  - publisher: "MedShadow Foundation"
    url: "https://medshadow.org"
    tier: 2
    used_for: "Recall details including Gas-X and duloxetine (06/15)"
  - publisher: "FDA.gov — Enforcement Reports"
    url: "https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/enforcement-reports"
    tier: 1
    used_for: "Primary recall notice — MUST VERIFY before publish"
  - publisher: "FDA — Nitrosamine Impurities Guidance"
    url: "https://www.fda.gov/drugs/drug-safety-and-availability/information-about-nitrosamine-impurities-medications"
    tier: 1
    used_for: "Carcinogen context"
```

⚠️ **Integrity note:** FDA enforcement report URL must be confirmed before publish. Exact manufacturer and lot codes required — do not publish without specific product identifiers.

⚠️ **Integrity note:** Prominently warn: carcinogen risk from nitrosamine contamination is a long-term cumulative exposure concern, NOT an acute toxicity emergency. Do not frame as "your antidepressant is poisoning you."

⚠️ **Integrity note:** Abrupt discontinuation of duloxetine can be more harmful than continuing a recalled lot while waiting for medical guidance. This must be clearly communicated.

**SEO:**
- Primary keyword: "duloxetine recall 2026"
- Supporting: "cymbalta generic recall carcinogen," "antidepressant recall FDA 2026," "duloxetine lot codes recalled," "can I stop taking duloxetine recall"
- Format: News article + FAQ schema
- Estimated word count: 900–1,100

**Expert needed:** Psychiatrist or pharmacist quote on discontinuation risk — use published guidance from FDA medication guide or APA statement if direct quote unavailable.

---

### BRIEF 04 — P2 · SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "Shingles Vaccine Linked to Reduced Dementia Risk — New Research"
primary_entity: "shingles vaccine dementia risk"
signal_type: study_or_research
allowed_category: "medical research and clinical trials / aging and longevity"
trend_strength_score: 76
opportunity_score: 78
discover_score: 4
urgency: today
confidence: medium
content_status: new
source_count: 4
recommended_angle: >
  "Does the Shingles Vaccine Protect Your Brain? What a New Study Actually Found" —
  Research translation angle: what did the study measure, how strong is the evidence,
  who should update their vaccination calculus. Skeptical-but-balanced framing.
  Competitors covering this will write hype-forward headlines — differentiate with
  rigorous "what this means and what it doesn't" framing.
why_now: >
  Brown University study announcement on 06/15 generated credible coverage.
  Dementia prevention is among the highest-interest health topics for the 50+ audience
  segment of our target demographic. Shingrix (recombinant shingles vaccine) is
  widely available and already recommended for adults 50+, so this finding has
  immediate actionability for readers.
primary_headline: "New Study: Shingles Vaccine May Lower Dementia Risk — Here's What the Evidence Actually Shows"
```

**Alternate headlines:**
- "Could Getting Your Shingles Shot Protect Against Dementia? Researchers Think So — With Caveats"
- "The Surprising Brain Benefit of the Shingles Vaccine, Explained"

**Why now:** Convergence of aging + vaccination + dementia prevention in a single finding is rare and high-value. Audience immediately actionable (Shingrix is a recommended routine vaccine for 50+).

**Outline:**
1. **Lede:** A new study from Brown University found that people who received the shingles vaccine were significantly less likely to develop dementia — here's what that means
2. **What the study found:** Population studied, sample size, duration, key finding (% reduction in dementia risk)
3. **Why might a shingles vaccine affect the brain?** Two leading hypotheses: (a) varicella-zoster virus reactivation may trigger neuroinflammation → Alzheimer's pathology; (b) Shingrix's adjuvant system may stimulate broader immune protection. Distinguish hypothesis from established mechanism.
4. **How strong is this evidence?** Study design: observational vs. RCT. Limitations: confounding (healthier people more likely to get vaccinated), no causal proof established
5. **What this does NOT mean:** Not a dementia cure. Doesn't replace other prevention strategies. Observational association ≠ guaranteed protection
6. **Who should get the shingles vaccine (and who already should)?** CDC recommendation: Shingrix for adults 50+, regardless of prior chickenpox history or prior Zostavax. Two-dose series.
7. **Does this change anything about who should get vaccinated?** Expert perspective — this finding adds another data point but recommendation was already strong
8. **FAQ:** What if I already had shingles? Can I still get the vaccine? Is there an age it's too late?

**Key data points:**
- Brown University study details — publication name/DOI/PubMed [URL unverified — must locate before publish]
- CDC Shingrix recommendation: adults 50+, two doses 2–6 months apart
- Shingles incidence: ~1 million cases/year in US (CDC)
- Dementia incidence: ~10 million new cases/year globally (WHO)

**Sources:**
```yaml
sources:
  - publisher: "Brown University — Study Announcement"
    url: "https://www.brown.edu/news"
    tier: 2
    used_for: "Study announcement 06/15 [locate specific page and journal citation]"
  - publisher: "CDC — Shingles Vaccine"
    url: "https://www.cdc.gov/vaccines/vpd/shingles/index.html"
    tier: 1
    used_for: "Vaccine recommendation and dosing guidance"
  - publisher: "Journal [to be confirmed]"
    url: "[URL unverified — locate DOI/PubMed before publish]"
    tier: 1
    used_for: "Primary study data"
  - publisher: "WHO — Dementia"
    url: "https://www.who.int/news-room/fact-sheets/detail/dementia"
    tier: 1
    used_for: "Dementia burden statistics"
```

⚠️ **Integrity note:** This is an observational study (based on announcement framing) — correlation, not causation. Cannot say "shingles vaccine prevents dementia." Must say "associated with reduced risk" and explain healthy vaccinee bias as a limitation.

⚠️ **Integrity note:** Journal DOI/PubMed record must be found before publish. Brown University announcement is credible but insufficient alone.

**SEO:**
- Primary keyword: "shingles vaccine dementia risk"
- Supporting: "shingrix dementia protection," "shingles vaccine brain health," "shingles vaccine benefits 2026," "does shingles vaccine prevent Alzheimer's"
- Format: Research explainer + FAQ schema
- Cluster: Aging & Longevity → Vaccines → Brain Health
- Estimated word count: 1,000–1,300

**Expert needed:** Neurologist or geriatrician quote on mechanism hypothesis; Infectious disease physician on vaccine recommendation context. Use named researchers from the Brown study or CDC advisory committee published statements.

---

### BRIEF 05 — P2 · SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "GLP-1 Drugs (Ozempic/Wegovy) May Save Over $192,000 in Lifetime Medical Costs for People With Obesity"
primary_entity: "GLP-1 obesity treatment lifetime cost savings"
signal_type: study_or_research
allowed_category: "nutrition and diet science / chronic disease management"
trend_strength_score: 74
opportunity_score: 76
discover_score: 4
urgency: today
confidence: medium
content_status: new
source_count: 3
recommended_angle: >
  "GLP-1 Drugs for Obesity Could Save $192K in Lifetime Medical Costs — But There's a Catch"
  — Frame around the full picture: significant cost savings vs. high drug costs, insurance
  coverage gaps, access inequity. This is the angle competitors don't take — they write
  "GLP-1 saves money" without the structural critique that makes it useful journalism.
why_now: >
  Fortune study coverage on 06/14 is within the freshness window. GLP-1 search interest
  is persistently high (weight loss +7 7d-delta in Trends). The cost framing directly
  addresses audience anxiety about whether GLP-1s are "worth it" financially — a top
  audience question. Cost-effectiveness data is rare; most GLP-1 coverage is clinical.
primary_headline: "GLP-1 Drugs Could Save People With Obesity $192,000+ Over Their Lifetime — But Access Remains the Problem"
```

**Alternate headlines:**
- "The True Cost-Benefit of Ozempic: New Study Puts a $192K Lifetime Value on Treating Obesity"
- "Are GLP-1 Drugs Worth the Cost? A New Study Does the Math — and the Answer Is Complicated"

**Why now:** Financial framing on GLP-1s fills a genuine SERP gap. Most content is clinical ("does it work?"); cost-effectiveness angle addresses a real audience question ("can I justify this cost?") with new data.

**Outline:**
1. **Lede:** A new study estimates that treating obesity with GLP-1 receptor agonists may prevent enough downstream health costs to save more than $192,000 per person over a lifetime
2. **What was studied?** Modeling methodology: what medical conditions were included in the cost calculation? (Likely: T2D, cardiovascular events, hypertension, cancer, musculoskeletal conditions) — confirm from journal
3. **What the $192,000 includes:** Break down: reduced hospitalizations, fewer diabetes medications, lower cardiovascular event costs, etc.
4. **What it doesn't include — the catch:** Drug cost itself (~$10,000–$16,000/year without insurance), access gaps, the fact that most people can't get or keep coverage, discontinuation rates
5. **The insurance and access reality:** Medicare now covers GLP-1s for cardiovascular risk? Coverage map. What percentage of people with obesity can access them?
6. **Who benefits most?** Higher BMI, metabolic comorbidities, cardiovascular risk — the study's likely highest-savings subgroup
7. **What this means for the policy debate:** Cost-effectiveness argument is being made to expand insurance coverage. Advocates' and payers' perspectives.
8. **FAQ:** Does this mean insurance should cover it? Is there a cheaper alternative? What if I stop taking it — do the savings disappear?

**Key data points:**
- $192,000+ lifetime medical cost savings (Fortune, 06/14 — confirm study and journal)
- Current GLP-1 drug cost: semaglutide (Wegovy) ~$1,300–$1,400/month list price; with insurance/Novo program: varies
- Obesity affects ~42% of US adults (CDC)
- Estimated annual healthcare cost attributable to obesity: $173 billion (CDC)

**Sources:**
```yaml
sources:
  - publisher: "Fortune"
    url: "https://fortune.com/well/2026/06/14/glp-1-obesity-lifetime-medical-costs-study/"
    tier: 2
    used_for: "Study summary and $192K figure [URL pattern — verify exact URL]"
  - publisher: "Journal [to be confirmed]"
    url: "[URL unverified — locate study DOI before publish]"
    tier: 1
    used_for: "Primary cost-modeling methodology"
  - publisher: "CDC — Obesity Data"
    url: "https://www.cdc.gov/obesity/data/adult.html"
    tier: 1
    used_for: "US obesity prevalence and economic burden statistics"
```

⚠️ **Integrity note:** $192K is a modeled projection, not observed real-world savings. Must be framed as modeling study, not clinical trial result. Confirm study type (economic modeling, observational, or simulation).

⚠️ **Integrity note:** Journal citation and DOI must be confirmed before publish. Fortune is a credible secondary source but insufficient alone for a health cost-effectiveness claim.

**SEO:**
- Primary keyword: "GLP-1 cost savings obesity"
- Supporting: "Ozempic worth it cost," "GLP-1 lifetime medical costs study," "Wegovy obesity savings," "does insurance cover Ozempic 2026"
- Format: Research explainer + FAQ
- Cluster: GLP-1 / Weight Management / Chronic Disease
- Estimated word count: 1,100–1,400

**Expert needed:** Endocrinologist or health economist. Use named study authors or existing STAT News / NEJM perspective quotes on GLP-1 cost-effectiveness debate.

---

### BRIEF 06 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "NIH Study: Lifestyle Intervention Lowers Risk of Multiple Chronic Conditions in Prediabetes"
primary_entity: "prediabetes lifestyle intervention multiple chronic conditions"
signal_type: clinical_trial
allowed_category: "chronic disease management / medical research and clinical trials"
trend_strength_score: 70
opportunity_score: 72
discover_score: 3
urgency: this_week
confidence: high
content_status: new
source_count: 3
recommended_angle: >
  Beyond just preventing type 2 diabetes — NIH study shows lifestyle changes in
  prediabetes reduce risk of heart disease, kidney disease, and other chronic
  conditions simultaneously. Lead with the multi-condition framing, which is novel
  and more compelling than the standard "diet prevents diabetes" story.
why_now: NIH.gov published 06/15 — institutional primary source confirmed. Prediabetes affects 98 million US adults. High search interest in nutrition (+9 7d-delta) and gut health (+12) supports audience relevance.
primary_headline: "Lifestyle Changes for Prediabetes Do More Than Prevent Diabetes, NIH Study Finds"
```

**Alternate headline:** "The Case for Lifestyle Medicine: NIH Confirms Prediabetes Interventions Cut Risk Across Multiple Diseases"

**Key data points:**
- NIH study URL: [https://www.nih.gov/news-events/news-releases](https://www.nih.gov/news-events/nih-research-matters) — locate specific 06/15 release
- 98 million US adults have prediabetes (CDC); ~80% unaware
- Conditions measured: type 2 diabetes, cardiovascular disease, chronic kidney disease, sleep apnea, nonalcoholic fatty liver disease (confirm from NIH release)
- Intervention: structured lifestyle program (diet + physical activity + behavior support)

**Integrity flags:** Confirm whether this is observational data analysis of DPP (Diabetes Prevention Program) or a new trial. Frame correctly — "structured program" not "just eat better."

**Sources:**
```yaml
sources:
  - publisher: "NIH.gov"
    url: "https://www.nih.gov/news-events/nih-research-matters"
    tier: 1
    used_for: "Primary study release 06/15"
  - publisher: "ClinicalTrials.gov"
    url: "https://clinicaltrials.gov"
    tier: 1
    used_for: "Trial record confirmation"
  - publisher: "CDC — Prediabetes"
    url: "https://www.cdc.gov/diabetes/prevention/index.html"
    tier: 1
    used_for: "Prediabetes prevalence and DPP program context"
```

**SEO:** Primary keyword: "prediabetes lifestyle changes benefits" | Format: Research explainer + action guide | Estimated word count: 900–1,100 | Expert: Endocrinologist or registered dietitian

---

### BRIEF 07 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Pancreatic Cancer: Two Advances Fuel New Optimism in Treatment"
primary_entity: "pancreatic cancer treatment advances 2026"
signal_type: study_or_research
allowed_category: "medical research and clinical trials / chronic disease management"
trend_strength_score: 68
opportunity_score: 70
discover_score: 3
urgency: this_week
confidence: medium
content_status: new
source_count: 4
recommended_angle: >
  "Two Breakthroughs in Pancreatic Cancer: What the Science Actually Promises (and
  What It Doesn't Yet)" — Balanced progress narrative: acknowledge that pancreatic
  cancer has one of the worst 5-year survival rates, contextualize what these advances
  change vs. what the prognosis reality still is. Avoids both false hope and
  unnecessary pessimism.
why_now: Mayo Clinic published "2 major advances fuel new optimism" (06/18) + Cedars-Sinai reported a drug that may double survival time (06/15). Two institutional sources in the same cycle signals genuine clinical momentum.
primary_headline: "Pancreatic Cancer Research Is Having a Breakthrough Moment — Here's What's Actually Changed"
```

**Key data points:**
- Pancreatic cancer 5-year survival rate: ~13% overall; ~3% if distant stage at diagnosis (NCI SEER)
- Mayo Clinic advance 1: [confirm from mayo.edu/news — likely early detection or surgical technique]
- Cedars-Sinai advance 2: drug candidate that "may double survival time" — confirm drug name, trial phase, patient population from Cedars-Sinai clinical trial page
- ~66,440 new US pancreatic cancer diagnoses expected in 2026 (ACS estimate)

**Sources:**
```yaml
sources:
  - publisher: "Mayo Clinic"
    url: "https://newsnetwork.mayoclinic.org"
    tier: 1
    used_for: "06/18 report on two advances"
  - publisher: "Cedars-Sinai"
    url: "https://www.cedars-sinai.org/newsroom"
    tier: 1
    used_for: "Drug doubling survival time report 06/15"
  - publisher: "NCI SEER"
    url: "https://seer.cancer.gov/statfacts/html/pancreas.html"
    tier: 1
    used_for: "Survival rate statistics"
  - publisher: "American Cancer Society"
    url: "https://www.cancer.org/cancer/types/pancreatic-cancer"
    tier: 1
    used_for: "Incidence statistics"
```

⚠️ **Integrity note:** "Double survival time" is a significant claim — confirm drug name, trial phase (Phase I/II/III), comparator used, and patient population before publish. Phase I data should not be presented as treatment ready.

**SEO:** Primary keyword: "pancreatic cancer treatment 2026" | Format: Medical research explainer | Estimated word count: 1,000–1,200 | Expert: Oncologist (GI/pancreatic specialty)

---

### BRIEF 08 — P3 · SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Global Clinical Trial Identifies Safest, Most Effective Antibiotics for Staph Bloodstream Infections"
primary_entity: "golden staph bloodstream infection antibiotic trial"
signal_type: clinical_trial
allowed_category: "medical research and clinical trials / infectious disease"
trend_strength_score: 65
opportunity_score: 68
discover_score: 3
urgency: this_week
confidence: medium
content_status: new
source_count: 2
recommended_angle: >
  "Scientists Just Ran the World's Largest Staph Infection Trial — Here's What They Found
  About the Best Antibiotics" — Translate clinical trial results for a general audience:
  what Staphylococcus aureus (golden staph) is, why bloodstream infections are so
  dangerous, what the trial compared, and what changed in standard of care.
  AMR (antimicrobial resistance) angle as secondary hook.
why_now: Medical Xpress report 06/18 on global trial results — novel "world's largest" framing gives differentiation hook. Antimicrobial resistance is a growing public health priority.
primary_headline: "The World's Largest Staph Infection Trial Just Reported — Here's What Doctors Will Do Differently"
```

**Key data points:**
- Staphylococcus aureus bloodstream infection mortality rate: 15–50% depending on MRSA vs. MSSA and patient profile
- Trial scope: global, largest ever for this indication — confirm specific antibiotic names from Medical Xpress article
- Antimicrobial resistance: WHO lists drug-resistant S. aureus as a priority pathogen

**Sources:**
```yaml
sources:
  - publisher: "Medical Xpress"
    url: "https://medicalxpress.com"
    tier: 2
    used_for: "Trial results report 06/18 [locate specific URL]"
  - publisher: "Journal [to be confirmed]"
    url: "[URL unverified — find journal name and DOI from Medical Xpress article]"
    tier: 1
    used_for: "Primary trial data"
  - publisher: "WHO — AMR Priority Pathogens"
    url: "https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed"
    tier: 1
    used_for: "AMR context"
```

⚠️ **Integrity note:** Journal name and DOI must be found before publish. Identify specific antibiotic names and comparators — "most effective" claim requires quantified outcome data.

**SEO:** Primary keyword: "golden staph bloodstream infection treatment" | Supporting: "Staphylococcus aureus antibiotics," "best antibiotic for staph infection 2026," "MRSA bloodstream infection treatment" | Format: Research explainer | Estimated word count: 800–1,000

---

### BRIEF 09 — P4 · EVERGREEN QUEUE

```yaml
priority_level: P4
publish_timing: evergreen
topic: "RFK Jr.'s $700 Million Mental Health Announcement: What the Grants Actually Are"
primary_entity: "RFK Jr mental health funding $700 million"
signal_type: policy_or_regulatory_change
allowed_category: "public health and epidemiology / mental health and psychology"
trend_strength_score: 58
opportunity_score: 62
discover_score: 3
urgency: this_week
confidence: medium
content_status: new
source_count: 2
recommended_angle: >
  Skeptical accountability angle — STAT News reported that experts say these grants
  "aren't new." The differentiated story is: what is the actual new money vs.
  repackaged existing grants? What real-world mental health services will this fund?
  Who benefits? This is STAT-sourced skepticism that general health media has not
  amplified.
why_now: STAT News 06/17 is the primary source; mental health search interest remains elevated (48, -4 7d-delta). Audience trust is served better by skeptical clarity than by amplifying a press release.
primary_headline: "RFK Jr. Says He's Delivering $700M for Mental Health. Experts Say Much of It Was Already Funded."
```

**Alternate headline:** "The Real Story Behind the $700 Million Mental Health Announcement"

**Key data points:**
- STAT News (06/17): experts say grants aren't new — confirm which grants, which agencies
- Mental health treatment gap: ~57% of US adults with mental illness receive no treatment (SAMHSA)
- GetActive.gov launch context (HHS.gov 06/15) — is this part of same initiative?

**Sources:**
```yaml
sources:
  - publisher: "STAT News"
    url: "https://www.statnews.com"
    tier: 1
    used_for: "Expert skepticism angle 06/17 [locate specific article URL]"
  - publisher: "HHS.gov"
    url: "https://www.hhs.gov"
    tier: 1
    used_for: "Secretary Kennedy announcement context 06/15"
  - publisher: "SAMHSA"
    url: "https://www.samhsa.gov/data/"
    tier: 1
    used_for: "Mental health treatment gap statistics"
```

⚠️ **Integrity note:** This story involves a current Cabinet secretary's public statements — use factual framing and quote expert skepticism directly from STAT. Do not editorialize against specific policy positions.

**SEO:** Primary keyword: "RFK mental health funding 2026" | Supporting: "SAMHSA mental health grants," "HHS mental health announcement 2026" | Format: News analysis | Estimated word count: 700–900

---

## REJECTED TOPICS LOG

| Topic | Rejection Reason |
|---|---|
| Anne Hathaway pregnant (Google Trends Trending Now) | Off-category: celebrity gossip; no health science angle |
| Jeremy Clarkson health / David Bromstad health (rising queries) | Off-category: celebrity health gossip; no verified medical claim with editorial value |
| California health insurance tax increase (CalMatters, KCRA) | Off-category: state financial/tax policy; insufficient health-science angle |
| AI making healthcare less affordable (Axios) | Borderline fail: tech/policy frame dominates; no primary health data; category borderline |
| Samsung VivaTech wellness solutions announcement | Off-category: brand/product launch; no health evidence angle |
| Bank of America wellness spending trend | Off-category: financial services brand content |
| Balenciaga wellness kick (WWD) | Off-category: fashion/celebrity wellness trend |
| Wearables in clinical research (Clinical Trials Arena) | Weak signal: industry trade content without patient-facing editorial value |
| LungSMART bilingual digital health content (Rethinking Clinical Trials) | Weak signal: too narrow/process-focused; no consumer health angle |
| Novo Nordisk clinical trial data cyberattack (HIPAA Journal) | Off-category: IT security/legal; no patient health content angle |
| USF liver cancer drug funding (University of South Florida) | Weak signal: funding announcement only, not results; single institutional source |
| Northwestern Medicine cancer trial recruitment AI (Business Journals) | Weak signal: clinical operations/recruitment process; no patient outcome data |
| Lassa fever vaccine first-in-human (University of Maryland) | Monitored (not rejected): limited US audience relevance at current stage; no US exposure risk; insufficient urgency for general audience |
| Psilocybin USC clinical study launch (Keck School of Medicine) | Monitored: funding/launch announcement only; no results to report; clinical trial not yet active |
| AI medical diagnosis — AMIE Google (blog.google) | Monitored via 02b: primary source is blog.google; no peer-reviewed publication confirmed at time of run |
| Gas-X coolant contamination / supplement salmonella recall (MedShadow) | Monitored via 02b: single secondary source; FDA notice not independently confirmed at run time |
| Gallup healthcare affordability at 5-year low | Monitored: strong data signal, but primarily policy/financial framing with thin actionable health angle for our audience; defer for potential policy-health angle development |
| NOAA North Atlantic Right Whale health updates | Off-category: marine biology / wildlife |
| Colorado traffic fatality study (CDOT) | Off-category: transportation safety |
| Yale study: physical/mental capacity to disability before death | Weak signal: single institutional press release; limited audience actionability |
| Music therapy cancer anxiety (Mount Sinai) | Weak signal: single-institution press release; small cohort likely; needs peer-reviewed confirmation |
| Czechia clinical trials hub (Euractiv) | Off-category: European regulatory/business |
| Crumbl dirty soda nutrition facts (Google Trends rising) | Off-category: branded fast food; celebrity brand rather than nutrition science |
| Sauerkraut / Trump cabinet diet (Google Trends rising) | Off-category: political celebrity diet trend |
| Global Wellness Day 2026 (Google Trends rising) | Off-category: commercial wellness event; no editorial health science angle |
| CMS office for health technology (Healthcare Dive) | Weak signal: regulatory org chart change; no patient-facing health content |
| AI in therapy — patients bringing AI (APA) | Monitored: credible source but thin data behind this cycle; better as a longer-form evergreen in 2–3 weeks |
| Hutchinson/Berkeleyside wellness center closure | Too local/state-specific; insufficient national audience value |

---

## INTEGRITY FLAGS — CONSOLIDATED

| Topic | Flag |
|---|---|
| **Alfredo Sauce Recall** | ⚠️ Specific brand name and lot codes must be pulled directly from FDA recall page. Do not publish without product identifiers. |
| **Infant Formula Botulism** | ⚠️ Active investigation — not confirmed causation. Language must reflect investigational status. Infant botulism ≠ adult foodborne botulism — explain distinction to prevent panic. Pull exact product details from FDA outbreak page before publish. |
| **Antidepressant (Duloxetine) Recall** | ⚠️ FDA enforcement report URL must be confirmed before publish. ⚠️ Nitrosamine risk is long-term/cumulative — not acute toxicity. ⚠️ Abrupt duloxetine discontinuation can cause serious withdrawal syndrome — must prominently warn patients to consult prescriber before stopping. |
| **Shingles Vaccine / Dementia** | ⚠️ Observational study — association, not causation. Must not claim vaccine "prevents" dementia. ⚠️ Healthy vaccinee bias must be acknowledged as limitation. ⚠️ Journal DOI/PubMed must be confirmed. |
| **GLP-1 Cost Savings $192K** | ⚠️ Economic modeling study — projected savings, not observed. Frame as model, not clinical trial. ⚠️ Journal citation and DOI must be confirmed. ⚠️ Drug acquisition cost and access barriers must be included for editorial balance. |
| **Pancreatic Cancer Advances** | ⚠️ "Double survival time" is a significant claim — confirm drug name, trial phase, comparator, and patient population before publish. Phase I findings must not be presented as standard-of-care ready. |
| **Golden Staph Antibiotic Trial** | ⚠️ Journal DOI must be found before publish. "Most effective" claim requires quantified outcome data from primary source. |
| **RFK $700M Mental Health** | ⚠️ Factual framing required; quote STAT expert skepticism directly. Do not editorialize against policy positions. |

---

## RUN NOTES

```yaml
run_date: "2026-06-19"
niche: "health and wellness"
signals_reviewed: 144
topics_retained: 9
topics_rejected: 135
p1_count: 2
p2_count: 3
p3_count: 3
p4_count: 1
p5_monitor_count: 6
integrity_flags: 8
top_topic: "Alfredo Sauce Salmonella Recall — FDA Class I"
key_themes:
  - "FDA food safety recalls (salmonella, botulism)"
  - "Drug safety recalls (antidepressant carcinogen)"
  - "Vaccine benefits beyond primary indication (shingles/dementia)"
  - "GLP-1/obesity cost-effectiveness"
  - "Prediabetes lifestyle intervention"
  - "Pancreatic cancer treatment advances"
  - "Antimicrobial resistance / antibiotic trials"
tools_used:
  - "SerpAPI Google News (pre-fetch, 144 signals)"
  - "SerpAPI Google Trends (pre-fetch, 7-day interest for 9 keywords)"
tools_unavailable: []
dashboard_output: "outputs/daily_newsroom_dashboard/2026-06-19.html"
notes: >
  site_url not configured — self-check skipped; content_status assignments use
  competitor-check fallback; all candidates marked new with disclosure.
  deferred_topics.yaml not found — no deferred topics carried forward.
  run_history.yaml not found — cross-run staleness check and recurring theme
  flagging not performed; will initialize on this run.
  Google Trends shows strongest positive 7d momentum in: fitness (+13),
  gut health (+12), nutrition (+9), weight loss (+7). Gut health and nutrition
  signals are supporting evidence for retained candidates but did not independently
  produce a standalone candidate in this cycle at the minimum scoring thresholds.
  Monitored topics (Gas-X recall, AI therapy, psilocybin launch, Lassa vaccine,
  AI medical diagnosis AMIE) should be rechecked in 48–72 hours for primary
  source confirmation or new developments.
  Two P1 candidates (Alfredo sauce recall, infant formula botulism) should be
  published as soon as FDA recall page product details are confirmed. Both are
  active consumer safety events.
```

---

*Pipeline complete. Next action: Confirm FDA recall page URLs for P1 briefs, locate journal DOIs for P2 study briefs, then publish P1 content immediately. Archive this run to `data/run_history.yaml`.*